Clinical Trials Logo

Risk-directed Therapy clinical trials

View clinical trials related to Risk-directed Therapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT03620955 Recruiting - MRD Clinical Trials

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Start date: August 10, 2018
Phase:
Study type: Observational

Risk-stratified therapy based on molecular and cytogenetic for acute myeloid leukemia (AML) is well accepted and benefits patients' survival. However, neither every patient with low risk factors obtains better survival, nor all high risk patients experience worse outcome. Lots of data have shown that the early treatment response presenting as minimal residual disease (MRD) has an important role in prognostic prediction. In this study, we perform risk stratification based on not only Cytogenetic and Molecular characteristic, but also MRD after three courses of chemo therapy in AML cohort. Patients with MRD positive would be moved to a higher risk class. And then the risk-stratified therapy should be considered according to the new risk stratification.